Clinical Trials Directory

Trials / Conditions / T-lymphoblastic Lymphoma

T-lymphoblastic Lymphoma

22 registered clinical trials studyying T-lymphoblastic Lymphoma — 10 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingTesting the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphobl
NCT07072585
Children's Oncology GroupPhase 2 / Phase 3
Not Yet RecruitingEfficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL
NCT07476027
Institute of Hematology & Blood Diseases Hospital, ChinaEARLY_Phase 1
RecruitingAdaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
NCT07523555
Beijing BiotechPhase 1 / Phase 2
Not Yet RecruitingAllo-HSCT vs ASCT in Adult T-LBL
NCT06741813
Peking University People's HospitalN/A
RecruitingTargeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma
NCT06633341
Zhejiang UniversityEARLY_Phase 1
WithdrawnAdding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemi
NCT06210750
National Cancer Institute (NCI)Phase 2
Not Yet RecruitingThe Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic
NCT06434467
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
RecruitingLinperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
NCT06376721
Beijing Tongren HospitalPhase 1 / Phase 2
RecruitingCD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
NCT06136364
Hebei Senlang Biotechnology Inc., Ltd.Phase 1
UnknownVenetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia
NCT05576532
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicinePhase 2
WithdrawnCryopreserved MMUD BM With PTCy for Hematologic Malignancies
NCT05170828
Ossium Health, Inc.Phase 1
WithdrawnA Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL
NCT04860817
920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaEARLY_Phase 1
UnknownAdvancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL
NCT04582487
Gruppo Italiano Malattie EMatologiche dell'AdultoN/A
SuspendedAnti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
NCT04828174
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicinePhase 1
RecruitingStudy to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Ly
NCT04315324
SWOG Cancer Research NetworkPhase 1 / Phase 2
UnknownRD13-01 for Patients With r/r CD7+ T-ALL/T-LBL
NCT04620655
Min XiangN/A
UnknownCD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic L
NCT04004637
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Phase 1
WithdrawnEtoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase
NCT02538926
University of WashingtonPhase 2
UnknownA Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma
NCT03558412
Mingzhi ZhangPhase 4
TerminatedDonor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01028716
Fred Hutchinson Cancer CenterPhase 2
RecruitingCombination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymph
NCT00501826
M.D. Anderson Cancer CenterPhase 2
CompletedCombination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia o
NCT00408005
National Cancer Institute (NCI)Phase 3